QQ客服 官方微博 反馈留言

浏览/检索结果: 共8条，第1-8条 帮助 已选(0)清除 条数/页：5101520253035404550556065707580859095100   排序方式：请选择作者升序作者降序题名升序题名降序发表日期升序发表日期降序提交时间升序提交时间降序 High-density lipoprotein increases the uptake of oxidized low density lipoprotein via PPARgamma/CD36 pathway in inflammatory adipocytes. 期刊论文 INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES, 2015, 卷号: 11, 期号: 3, 页码: 256-265 作者:  Zhong, Qiaoqing;  Zhao, Shuiping;  Yu, Bilian;  Wang, Xing;  Matyal, Robina 收藏  |  浏览/下载：2/0  |  提交时间：2019/12/03 Lipoprotein  Atherosclerosis  Inflammation  Lipopolysaccharide   High-density Lipoprotein Increases the Uptake of Oxidized Low Density Lipoprotein via PPAR gamma/CD36 Pathway in Inflammatory Adipocytes (SCI收录) 期刊论文 INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES, 2015, 卷号: 11, 页码: 256-265 作者:   收藏  |  浏览/下载：11/0  |  提交时间：2019/04/25 Lipoprotein  Atherosclerosis  Inflammation  Lipopolysaccharide   High-density lipoprotein increases the uptake of oxidized low density lipoprotein via PPARgamma/CD36 pathway in inflammatory adipocytes. 期刊论文 INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES, 2015, 卷号: 11, 期号: 3, 页码: 256-265 作者:  Zhong, Qiaoqing;  Zhao, Shuiping;  Yu, Bilian;  Wang, Xing;  Matyal, Robina 收藏  |  浏览/下载：1/0  |  提交时间：2019/12/27 Lipoprotein  Atherosclerosis  Inflammation  Lipopolysaccharide   Prevalence of dyslipidaemia in patients treated with lipid-lowering agents in China: Results of the DYSlipidemia International Study (DYSIS) 期刊论文 Atherosclerosis, 2014, 卷号: 235, 期号: 2, 页码: 463-469 作者:  Zhao, Shuiping;  Wang, Yongjun;  Mu, Yiming;  Yu, Bilian;  Ye, Ping 收藏  |  浏览/下载：8/0  |  提交时间：2019/12/03 Cardiovascular diseases  Dyslipidaemia  Statin  Lipid-lowering agents  LDL cholesterol  Non-HDL cholesterol   Lipid-lowering therapy and lipid goal attainment in patients with metabolic syndrome in China: subgroup analysis of the Dyslipidemia International Study-China (DYSIS-China) 会议论文 JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2014-10-21 作者:  Wang Fan;  Hu Dayi;  Zhao Shuiping;  Wang Yongjun;  Mu Yiming 收藏  |  浏览/下载：15/0  |  提交时间：2020/01/13 Prevalence of dyslipidaemia in patients treated with lipid-lowering agents in China: Results of the DYSlipidemia International Study (DYSIS) 期刊论文 2014, 卷号: 235, 期号: 2, 页码: 463-469 作者:  Zhao, Shuiping;  Wang, Yongjun;  Mu, Yiming;  Yu, Bilian;  Ye, Ping 收藏  |  浏览/下载：3/0  |  提交时间：2020/01/13 Cardiovascular diseases  Dyslipidaemia  Statin  Lipid-lowering agents  LDL cholesterol  Non-HDL cholesterol   Tissue factor pathway inhibitor-2 is downregulated by ox-LDL and inhibits ox-LDL induced vascular smooth muscle cells proliferation and migration 期刊论文 THROMBOSIS RESEARCH, 2011, 卷号: 128, 期号: 2 作者:  Zhao, Bilian;  Luo, Xinping;  Shi, Haiming;  Ma, Duan 收藏  |  浏览/下载：8/0  |  提交时间：2019/12/19 tissue factor pathway inhibitor-2 (TFPI-2)  vascular smooth muscle cells (VSMCs)  proliferation  migration  atherosclerosis   The Role of von Willebrand Factor and ADAMTS13 in the No-Reflow Phenomenon after Primary Percutaneous Coronary Intervention 期刊论文 TEXAS HEART INSTITUTE JOURNAL, 2011, 卷号: 38, 期号: 5 作者:  Zhao, Bilian;  Li, Jian;  Luo, Xinping;  Zhou, Qing;  Chen, Hua 收藏  |  浏览/下载：4/0  |  提交时间：2019/12/19 ADAMTS13 protein, human  angioplasty, balloon, coronary/adverse effects  microcirculation  myocardial ischemia  myocardial reperfusion  no-reflow phenomenon/drug therapy  predictive value of tests  prospective studies  von Willebrand factor